BMRN:NASDAQ
Biomarin Pharmaceutical Inc
57,54 US$
arrow_upward
+0,63%(+0,36) 1K
57,54 US$
0,00% (0,00)
bedtimeYopilgandan keyin
Savdolar yopilgan: 5-okt, 16:00:01 (GMT-4) · USD
search
Barcha belgilar
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_autoBMRN tikeri uchun statistika yaratilmoqda...
Ochish
57,11 US$
Yuqori
58,11 US$
Past
56,82 US$
Bozor kapitali
11,14 mlrd
Oʻrtacha hajm
1,93 mln
Hajmi
1,00
P/E koeffitsiyenti
155,12
52 haftalik eng yuqori
70,98 US$
52 haftalik eng past
49,26 US$
Aksiya boʻyicha daromad
0,37 US$
Beta
0,22
Muomaladagi aksiyalar
193,57 mln
Xodimlar soni
3 ming
Ochish
57,11 US$
Yuqori
58,11 US$
Past
56,82 US$
Bozor kapitali
11,14 mlrd
Oʻrtacha hajm
1,93 mln
Hajmi
1,00
P/E koeffitsiyenti
155,12
52 haftalik eng yuqori
70,98 US$
52 haftalik eng past
49,26 US$
Aksiya boʻyicha daromad
0,37 US$
Beta
0,22
Muomaladagi aksiyalar
193,57 mln
Xodimlar soni
3 ming
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
Investing.com UK
·
14 soat oldin
BioMarin names Cara Bauer as chief people officer By Investing.com
PR Newswire
·
14 soat oldin
BioMarin Appoints Cara Bauer as Chief People Officer
Profil
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies. BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria.
Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials. Wikipedia
Biomarin Pharmaceutical Inc haqida
CEOAlexander Hardy
Xodimlar soni3,22 ming
Asos solinganmar 1997
Bosh ofislarSan Rafael, Kaliforniya, Amerika Qo‘shma Shtatlari
Sektor-
Veb-saytbiomarin.com